ADC refers to Antibody-Drug Conjugate technology, a targeted cancer therapeutic modality combining monoclonal antibodies with cytotoxic payloads. Recent biotech M&A activity, including J&J's acquisition of Firefly Bio for $1B, underscores accelerating adoption in oncology pipelines.
Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.
Notes, edits, or content requests — sent directly to James.